Benzinga | Jul 16, 2020 07:06AM EDT

Benchmark Upgrades NextCure to Buy, Announces $17 Price Target

Benchmark analyst Aydin Huseynov upgrades NextCure (NASDAQ:NXTC) from Hold to Buy and announces $17 price target.